Association between preoperative neutrophil-to-lymphocyte ratio and malignant intraductal papillary mucinous neoplasms: A systematic review and meta-analysis

Figure 1  PRISMA flow diagram of eligible studies selection.

Figure 2 Forest plot of the association between elevated neutrophil-to-lymphocyte ratio and malignant intraductal papillary mucinous neoplasms. OR: Odds ratio; CI: Confidence interval; SE: Standard error; HK: Hartung-Knapp.

Figure 3 Subgroup analysis of the association between elevated neutrophil-to-lymphocyte ratio and malignant intraductal papillary mucinous neoplasms. A: Japan subgroup; B: Non-Japan subgroup; C: Neutrophil-to-lymphocyte ratio cut-off < 3 subgroup; D: Neutrophil-to-lymphocyte ratio cut-off ≥ 3 subgroup; E: Malignancy defined as invasive carcinoma alone; F: Malignancy defined as high-grade dysplasia and/or invasive carcinoma; G: Sample size < 100 subgroup; H: Sample size ≥ 100 subgroup. OR: Odds ratio; CI: Confidence interval; SE: Standard error; HK: Hartung-Knapp.

Figure 4 Leave-one-out sensitivity analysis of the association between elevated neutrophil-to-lymphocyte ratio and malignant intraductal papillary mucinous neoplasms. OR: Odds ratio; CI: Confidence interval; HK: Hartung-Knapp.

Figure 5  Funnel plot for assessment of publication bias.